Business

Announcement on Voluntarily Disclosure of Phase II Clinical Trial Results of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer

Announcement on Voluntarily Disclosure of Phase II Clinical Trial Results of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer

articleJiangsu Yahong Meditech Co., Ltd. Class ASeptember 25, 20244/news/announcement-on-voluntarily-disclosure-of-phase-ii-clinical-trial-results-of-oral-apl-1202-combined-with-tislelizumab-in-neoadjuvant-therapy-for-muscle-invasive-bladder-cancer
Announcement on Voluntarily Disclosure of Phase II Clinical Trial Results of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer

About this update from Jiangsu Yahong Meditech Co., Ltd. Class A

Announcement on Voluntarily Disclosure of Phase II Clinical Trial Results of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder CancerThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Jiangsu Yahong Meditech Co., Ltd. Class A